479611-96-6

Basic information

• Product Name: 4-(Methylsulfonyl)-piperidine HCl
• Synonyms: 4-(Methylsulfonyl)-piperidine HCl;4-(methylsulfonyl)piperidin-1-ium chloride;EOS-62313
• CAS NO: 479611-96-6
• Molecular Formula: C₆H₁₃NO₂S*ClH
• Molecular Weight: 199.69886
• Mol File: 479611-96-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Methylsulfonyl)-piperidine HCl(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylsulfonyl)-piperidine HCl(479611-96-6)
• EPA Substance Registry System: 4-(Methylsulfonyl)-piperidine HCl(479611-96-6)

Safety Data

• Hazardous Substances Data: 479611-96-6(Hazardous Substances Data)

Usage

General Description

4-(Methylsulfonyl)-piperidine HCl, also known as Tolvaptan, is a medication that is used to treat hyponatremia (low levels of sodium in the blood) and certain water retention conditions. It works by blocking the action of vasopressin, a hormone that causes the kidneys to retain water. By inhibiting vasopressin, Tolvaptan helps the body to excrete excess water and restore normal sodium levels. This chemical is a piperidine derivative with a methylsulfonyl group attached to the piperidine ring, and it is primarily available in the form of a hydrochloride salt. Tolvaptan is generally prescribed under medical supervision due to its potential side effects, which can include dehydration and liver damage.

Upstream product

• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 208245-69-6 4-methylsulfanylpiperidine-1-carboxylic acid tert-butyl ester 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 189205-49-0 4-methanesulfonylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1263479-96-4 trans-4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol 
• 1263480-62-1 2-fluoro-6-(4-methanesulfonylpiperidine-1-yl)benzaldehyde 
• 1190979-68-0 2-(4-(2-chloro-4-((4-(methylsulfonyl)piperidin-1-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine 

Relevant articles and documents

COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY

The present invention relates to compounds characterized by having a structure according to the following Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

Rational design of phosphoinositide 3-kinase inhibitors that exhibit selectivity over the phosphoinositide 3-kinase isoform

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.